Orogen Therapeutics

About Orogen Therapeutics

Orogen Therapeutics, Inc. operates as a private drug discovery company, established in 2023 and headquartered in Woburn, Massachusetts. The company is focused on developing novel, small-molecule therapeutics, particularly for immuno-inflammatory disorders.

The company's core technology revolves around a proprietary, AI-enabled platform that integrates DNA-encoded libraries (DEL) with computational chemistry and virtual screening. This platform, which includes the patent-pending FocusDEL™ technology, aims to accelerate the identification of promising chemical matter against clinically and commercially validated drug targets. Orogen's libraries contain over 40,000 building blocks, creating a screening potential of more than 16 billion compounds. The primary business objective is to develop oral small-molecule medicines as alternatives to existing biologic therapies for conditions such as psoriasis, rheumatoid arthritis, and Crohn's disease. The company's initial focus is on cytokine targets that have been validated by successful biologic drugs in the dermatology, rheumatology, and gastroenterology markets.

Financially, Orogen Therapeutics has secured significant initial capital to fund its research and development activities. In June 2023, the company raised $18.2 million in a Seed funding round. This financing was co-led by prominent life sciences investors Anterra Capital and Novalis LifeSciences, indicating strong market confidence in the company's platform and strategy. The company's scientific co-founder is Brett Chevalier. Orogen has also been strengthening its leadership, appointing former executives from Pfizer and Bayer Pharmaceuticals to its Board of Directors in May 2025 to guide its development and commercialization strategies.